Key facts
- Cytovation’s last known valuation is $13.2M (Jan 2018).
- It has raised $37.6M; the latest was Later Stage VC ($6.0M) in Apr 2025.
- Notable investors include Additio Investment Group, Canica, Sandwater.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cytovation
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytovation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytovation
Developer of a synthetic peptide designed to provide treatment for benign tumors and various types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action that guides the immune system to recognize and eradicate tumors, enabling patients to get treatment for cutaneous warts and malignant cancers.
- Sector
- Healthcare
- HQ
- Bergen, Norway
- Founded
- 2001
- Employees
- 10
- Website
- cytovation.com/
- Ownership
- Privately Held (backing)
Cytovation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytovation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytovation in its N-PORT filings yet. We sweep new filings monthly.